Alendronate, Etidronate, Risedronate, Raloxifene, Teriparatide and Strontium Ranelate.
NICE appraisals
Primary prevention
(January 2011)
Secondary prevention
(January 2011)
DSU reports
Assessing the feasibility of transforming the recommendations in TA160, TA161 and TA204 into absolute 10-year risk of fracture (PDF, 560KB) (May 2013)
Exploring the effect of the efficacy of strontium ranelate in preventing hip fracture in relation to cost-effectiveness (October 2010) (Report academic in confidence)
Comments on appraisal of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women (PDF, 149KB) (September 2010)
Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women / alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women – a review of comments submitted by consultees on the economic model (PDF, 692KB) (August 2009)
Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the cost-effectiveness of risedronate and strontium ranelate in those people who would be treated with generic alendronate (PDF, 204KB) (February 2008)
Adverse effects and persistence with therapy in patients taking oral alendronate, etidronate or risedronate: systematic reviews (PDF, 657KB) (October 2006)
Analyses of the cost effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide (PDF, 581KB) (September 2006)
The clinical effectiveness and cost effectiveness of prevention and treatment of osteoporosis (PDF, 160KB) (December 2003)
